AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05096481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV
Description: The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
Study NCT05193513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid expanders
Description: tow maxillary hybrid expanders supported anteriorly with tow miniscrews
Study NCT05096481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
Study NCT05096481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Diphtheria Vaccine
Description: Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
Study NCT05995938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfullnes-Based Cognitive Therapy
Description: Mindfullnes-Based Cognitive Therapy Effect on Adherence to Immunosuppressive Therapy in Liver Transplant Recipients
Study NCT06220162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide in combination with venetoclax and azacitidine (VAC)
Description: Enrolled patients were given chidamide 10 mg every day on days 1-14, azacitidine 75mg/m2 every day on days 1-7, and oral venetoclax began at 100mg on day 1 and increased stepwise over 3 days to reach the target dose of 400mg (100mg, 200mg, and 400mg) on days 1-28. Dose adjustments for concomitant venetoclax with CYP3A4 inhibitors were made according to the literature.
Study NCT05614726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Description: A multi-strain probiotic blend
Study NCT05614726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Description: A multi-strain probiotic blend
Study NCT03901001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus and oseltamivir
Description: Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Study NCT03901001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Study NCT06245421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DM934
Description: 1 drop in each eye, 4 to 6 times per day
Study NCT06245421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Théalose
Description: 1 drop in each eye, 4 to 6 times per day
Study NCT06301789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries
Description: Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
Study NCT06301789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries
Description: Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
Study NCT05044429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Lidocaine
Description: Patient will receive intravenous lidocaine 1.0-1.5 mg/kg/hour for 48 hours post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
Study NCT05044429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: Subject will receive 0.2% Ropivacaine at 6-10ml/hour through transversus abdominis plane (TAP) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
Study NCT05044429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum (QL) Block
Description: Subject will receive 0.2% Ropivacaine at 6-10ml/hour through quadratus lumborum (QL) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
Study NCT05074641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct myofascial release treatment
Description: Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
Study NCT05074641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowen therapy
Description: Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
Study NCT05430425 — intervention group
Intervention type: OTHER
Intervention: respiratory safety
Description: Which of the 3 lma selection methods is effective in ensuring respiratory safety?
Study NCT06218615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (Video)
Description: Watch video
Study NCT06218615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Answer survey questions
Study NCT05828459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-A201
Description: OT-A201 IV infusion qw or q2w
Study NCT05828459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMids
Description: Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
Study NCT05828459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
Study NCT05828459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
Study NCT05828459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBD Compound
Description: Combination regimen for hematological malignancy
Study NCT06138652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants completed games on an app and sessions with a mentor focused on alleviating anxiety over 8 weeks.
Study NCT04666545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MuST AKT
Description: A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
Study NCT04001010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPP011
Description: 1 capsule inhaled 3 times a day with a vaporizer device
Study NCT04001010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule inhaled 3 times a day with a vaporizer device
Study NCT04907214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Oral empagliflozin daily
Study NCT04710719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection
Description: Post surgical injection at site of keloid with TAC for 3 injections
Study NCT04710719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection and 5-fluorouracil injection
Description: Post surgical injection at site of keloid with TAC and 5FU for 3 injections
Study NCT05539443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Clinic Management (ICM)
Description: An in-person clinic management based on the intervention tested among stroke patients in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial
Study NCT05539443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive tailored telehealth management (ITTM)
Description: A remote-monitoring blood pressure (BP) management strategy incorporating individualized lifestyle coaching and care planning based on the HyperLink telehealth management trial
Study NCT04801732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan thoracic Sustained Natural Apophyseal Glides
Description: Extension Thoracic Sustained Natural Apophyseal Glides :~Patient position: The patient sits astride the end of the table with hands placed behind the neck to protract the scapulae allowing access to the mid thoracic spine for the therapist's hand.~Therapist position: Therapist stands on their most efficient side for a centrally applied Sustained Natural Apophyseal Glides.~Therapist grasp: The therapist's mobilizing hand (ulnar border) will apply a cephalad glide in line with the facet joint plane of the involved spinal level and the other arm holds the thoracic wall above the level to be mobilized.~Traction is applied prior to glide, which is achieved by therapist knee extension~Repetitions: Three sets of ten repetitions will be done after a trial for the patient to be familial with the technique.~and traditional treatment.
Study NCT06240481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Regimen
Description: toothpaste \& mouthwash
Study NCT06240481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Test Regimen
Description: toothpaste \& mouthwash
Study NCT06240481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Regimen
Description: toothpaste
Study NCT06240481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Regimen
Description: toothpaste
Study NCT04801732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatments
Description: includes: Ice pack and Pendulum exercise and shoulder range of motion (elevation, depression, flexion, abduction, rotations).Stretching exercise for internal rotators and posterior capsule.~Strengthening exercise will be isometric in nature include external shoulder rotators, internal rotators, biceps, deltoid, and scapular stabilizers (rhomboids, trapezius, serratus anterior, Latissimus Dorsi , and pectoralis major muscles).
Study NCT06408701 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood will be taken in larger quantity
Study NCT05358041 — intervention group
Intervention type: DEVICE
Intervention: Robotic Bronchoscopy
Description: Replace the Super-D EMN navigational platform with Ion Robotic bronchoscopy platform guided with shape sensing technology
Study NCT04650087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG
Description: Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Study NCT04650087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Study NCT04890405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized FMT
Description: The group includes 35 patients. They will receive standardized FMT. Fecal bacteria capsules are used for fecal bacteria transplantation, 16 capsules are used each time, each capsule contains 200mg of fecal bacteria, and it is used orally. It was given only once.
Study NCT04890405 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Precision Flora Transplantation
Description: The group includes 35 patients. They will receive Precision Flora Transplantation. They were used self-developed precision transplant capsules for precision flora transplantation. 4 capsules are used each time. Each capsule contains 400mg of various probiotics effective against diarrhea. It is used orally, once a day,for 28 days.
Study NCT05258422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy, 20 Gy in 1 fraction
Description: A single dose of focused radiation therapy of 20 Gy in 1 fraction to the PTV of the arrhythmogenic substrate
Study NCT00780728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study NCT05383508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Tobacco
Study NCT05383508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM35
Description: Nicotine concentration: 3.5 % e-liquid flavor: Menthol
Study NCT05383508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cig
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes
Study NCT05524090 — intervention group
Intervention type: OTHER
Intervention: Implementation - International best-practice care
Description: The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
Study NCT04891302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
Study NCT04891302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
Study NCT05268536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stabilization exercise
Description: Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
Study NCT05268536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance exercise
Description: resistance exercise
Study NCT06165211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature sound listening
Description: The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.
Study NCT06165211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Patients will watch the program they want on the bedside TV during hemodialysis.
Study NCT06003842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.
Study NCT06003842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.
Study NCT06003842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taping
Description: After the Kinesio® Tex application, it will remain in the body for 4 days, and then it will be applied 6 times in total, with a 3-day break. It will be stated that the area to be banded should not contain substances such as cream, hair or oil. Upper Trapeze taping will be performed by applying one end of the Y tape to the upper trapeze and the other end to the lower part of the spina scapula, by affixing the tape to the head of the shoulder while standing upright, and keeping the participant's ear tilted towards the other ear as much as possible. Before attaching the rest of the tape, the participant will be asked to bring the shoulder blades closer together and stand upright. In this position, using a mechanical correction technique along the medial line of the scapula along the spine, the rest of the tape will be adhered as an I tape with 35-50% tension.
Study NCT06331390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: niacinamide cosmetic product
Description: immortella skincare product
Study NCT05782803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises Group
Description: A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
Study NCT05222165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Hard gelatin capsules for oral use